Evidence map›Paper›PMID 26694869›Full record

ArticlePloS one2015

Basal Cell Carcinoma in Gorlin's Patients: a Matter of Fibroblasts-Led Protumoral Microenvironment?

Yannick Gache, Florence Brellier, Sophie Rouanet, Sahar Al-Qaraghuli, Maria Goncalves-Maia, Elodie Burty-Valin, Stéphanie Barnay, Sabine Scarzello, Martial Ruat, Nicolas Sevenet and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Leveraging Tissue Engineering for Skin Cancer Models.Advances in experimental medicine and biology · 2023
    Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Yannick GacheINSERM U1081-CNRS UMR7284 -UNS, Nice, France.
Florence BrellierCNRS FRE2939, Université de Paris Sud-Institut Gustave Roussy, Villejuif, France.
Sophie RouanetINSERM U1081-CNRS UMR7284 -UNS, Nice, France.
Sahar Al-QaraghuliINSERM U1081-CNRS UMR7284 -UNS, Nice, France.
Maria Goncalves-MaiaINSERM U1081-CNRS UMR7284 -UNS, Nice, France.
Elodie Burty-ValinCNRS FRE2939, Université de Paris Sud-Institut Gustave Roussy, Villejuif, France.
Stéphanie BarnayUMR 7138, Université Pierre-et-Marie-Curie, Paris, France.
Sabine ScarzelloINSERM U1081-CNRS UMR7284 -UNS, Nice, France.
Martial RuatCNRS UMR9197, Neuroscience Paris-Saclay Institute, Gif‑sur‑Yvette, France.
Nicolas SevenetINSERM U916 & Institut Bergonié, Laboratoire de génétique moléculaire, Bordeaux, France.
Marie-Françoise AvrilService de Dermatologie, Université Paris 5-APHP, Paris, France.
Thierry MagnaldoINSERM U1081-CNRS UMR7284 -UNS, Nice, France.
Centre National de la Recherche Scientifique · FRInserm · FRAssistance Publique – Hôpitaux de Paris · FRSorbonne Université · FRUniversité Côte d'Azur · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Basal cell carcinoma (BCC) is the commonest tumor in human. About 70% sporadic BCCs bear somatic mutations in the PATCHED1 tumor suppressor gene which encodes the receptor for the Sonic Hedgehog morphogen (SHH). PATCHED1 germinal mutations are associated with the dominant Nevoid Basal Cell Carcinoma Syndrome (NBCCS), a major hallmark of which is a high susceptibility to BCCs. Although the vast majority of sporadic BCCs arises exclusively in sun exposed skin areas, 40 to 50% BCCs from NBCCS patients develop in non photo-exposed skin. Since overwhelming evidences indicate that microenvironment may both be modified by- and influence the- epithelial tumor, we hypothesized that NBCCS fibroblasts could contribute to BCCs in NBCCS patients, notably those developing in non photo-exposed skin areas. The functional impact of NBCCS fibroblasts was then assessed in organotypic skin cultures with control keratinocytes. Onset of epidermal differentiation was delayed in the presence of primary NBCCS fibroblasts. Unexpectedly, keratinocyte proliferation was severely reduced and showed high levels of nuclear P53 in both organotypic skin cultures and in fibroblast-led conditioning experiments. However, in spite of increased levels of senescence associated β-galactosidase activity in keratinocytes cultured in the presence of medium conditioned by NBCCS fibroblasts, we failed to observe activation of P16 and P21 and then of bona fide features of senescence. Constitutive extinction of P53 in WT keratinocytes resulted in an invasive phenotype in the presence of NBCCS fibroblasts. Finally, we found that expression of SHH was limited to fibroblasts but was dependent on the presence of keratinocytes. Inhibition of SHH binding resulted in improved epidermal morphogenesis. Altogether, these data suggest that the repertoire of diffusible factors (including SHH) expressed by primary NBCCS fibroblasts generate a stress affecting keratinocytes behavior and epidermal homeostasis. Our findings suggest that defects in dermo/epidermal interactions could contribute to BCC susceptibility in NBCCS patients.

Indexed as

Tumor MicroenvironmentBasal Cell CarcinomaBasal Cell Nevus SyndromeCell DifferentiationCell ProliferationCells, CulturedCoculture TechniquesCulture Media, ConditionedFibroblastsHumansKeratinocytesMutationOrgan Culture TechniquesPatched-1 ReceptorPatched ReceptorsReceptors, Cell SurfaceCulture Media, ConditionedPatched-1 ReceptorPatched ReceptorsPTCH1 protein, humanReceptors, Cell SurfaceTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID26694869
PMCPMC4687848
OpenAlexW2207930995

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.